Format
Sort by

Send to

Choose Destination

Search results

Items: 8

1.

Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.

Shen L, Shah BR, Reyes EM, Thomas L, Wojdyla D, Diem P, Leiter LA, Charbonnel B, Mareev V, Horton ES, Haffner SM, Soska V, Holman R, Bethel MA, Schaper F, Sun JL, McMurray JJ, Califf RM, Krum H.

BMJ. 2013 Dec 9;347:f6745. doi: 10.1136/bmj.f6745. Erratum in: BMJ. 2014;348:f1339.

2.

Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.

Latini R, Staszewsky L, Sun JL, Bethel MA, Disertori M, Haffner SM, Holman RR, Chang F, Giles TD, Maggioni AP, Rutten GE, Standl E, Thomas L, Tognoni G, Califf RM, McMurray JJ.

Am Heart J. 2013 Nov;166(5):935-40.e1. doi: 10.1016/j.ahj.2013.08.012.

PMID:
24176451
3.

Effect of valsartan on the incidence of diabetes and cardiovascular events.

NAVIGATOR Study Group., McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM.

N Engl J Med. 2010 Apr 22;362(16):1477-90. doi: 10.1056/NEJMoa1001121. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.

4.

Effect of nateglinide on the incidence of diabetes and cardiovascular events.

NAVIGATOR Study Group., Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozár J, Califf RM.

N Engl J Med. 2010 Apr 22;362(16):1463-76. doi: 10.1056/NEJMoa1001122. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.

5.

Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.

Krum H, McMurray JJ, Horton E, Gerlock T, Holzhauer B, Zuurman L, Haffner SM, Bethel MA, Holman RR, Califf RM.

Cardiovasc Ther. 2010 Apr;28(2):124-32. doi: 10.1111/j.1755-5922.2010.00146.x.

PMID:
20184589
6.
7.

[Glinide(s), sulfonylurea(s)].

Arakawa M, Hirose T.

Nihon Rinsho. 2006 Nov;64(11):2107-12. Review. Japanese.

PMID:
17087304
8.

[Effects of nateglinide in impaired glucose tolerance subjects].

Hirose T.

Nihon Rinsho. 2005 Feb;63 Suppl 2:438-43. Review. Japanese. No abstract available.

PMID:
15779419
Items per page

Supplemental Content

Loading ...
Support Center